title: Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
abstract: Myelofibrosis (MF) is characterized by splenomegaly, blood count abnormalities, particularly cytopenias, and a propensity for transformation to acute leukemia. The current treatment approach is to ameliorate symptoms due to these abnormalities. Treatment with Janus kinase 2 inhibitors reduces spleen size and improves symptoms in patients with MF, but most of the patients eventually have disease progression and stop responding. Allogeneic stem cell transplantation remains the only curative option. However, its efficacy must be balanced against the risk of treatment-related death and long-term sequelae of transplant like chronic graft versus host disease. The challenge is to integrate treatment with Janus kinase inhibitors with allogeneic stem cell transplantation.
authors: Department of Stem Cell Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: riadfakih@hotmail.com.
authors: Riad
authors: R
authors: El Fakih
authors: Department of Stem Cell Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors: Uday
authors: U
authors: Popat
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism*; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D047428:Protein Kinase Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: Myelofibrosis; Myeloproliferative neoplasm; Stem cell transplant